

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7656984

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
OBSEVA S.A.	11/21/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	XOMA (US) LLC
<b>Street Address:</b>	2200 POWELL STREET
<b>Internal Address:</b>	SUITE 310
<b>City:</b>	EMERYVILLE
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94608
<b>PROPERTY NUMBERS Total: 9</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	10555934
<b>Application Number:</b>	62274674
<b>Application Number:</b>	62395664
<b>Application Number:</b>	62407918
<b>Application Number:</b>	16752961
<b>Application Number:</b>	62672278
<b>Application Number:</b>	16411974
<b>Application Number:</b>	62815077
<b>Application Number:</b>	63114233
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)428-7045
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6174280200
<b>Email:</b>	patentadministrator@clarkelbing.com
<b>Correspondent Name:</b>	CLARK & ELBING LLP
<b>Address Line 1:</b>	101 FEDERAL STREET
<b>Address Line 2:</b>	15TH FLOOR
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	51130-001001

<b>NAME OF SUBMITTER:</b>	KAREN L. ELBING, PH.D.
<b>SIGNATURE:</b>	/Karen L. Elbing, Ph.D./
<b>DATE SIGNED:</b>	11/21/2022
<b>Total Attachments: 16</b> source=51130-002, -020, -026, -045 Assignment#page1.tif source=51130-002, -020, -026, -045 Assignment#page2.tif source=51130-002, -020, -026, -045 Assignment#page3.tif source=51130-002, -020, -026, -045 Assignment#page4.tif source=51130-002, -020, -026, -045 Assignment#page5.tif source=51130-002, -020, -026, -045 Assignment#page6.tif source=51130-002, -020, -026, -045 Assignment#page7.tif source=51130-002, -020, -026, -045 Assignment#page8.tif source=51130-002, -020, -026, -045 Assignment#page9.tif source=51130-002, -020, -026, -045 Assignment#page10.tif source=51130-002, -020, -026, -045 Assignment#page11.tif source=51130-002, -020, -026, -045 Assignment#page12.tif source=51130-002, -020, -026, -045 Assignment#page13.tif source=51130-002, -020, -026, -045 Assignment#page14.tif source=51130-002, -020, -026, -045 Assignment#page15.tif source=51130-002, -020, -026, -045 Assignment#page16.tif	

## EXHIBIT A

### ASSIGNMENT OF PATENTS, KNOW-HOW, AND LICENSES

WHEREAS, **OBSEVA, SA**, a Swiss corporation having its principal place of business at Chemin des Aulx, 12, 1228 Plan-les-Ouates, Geneva, Switzerland (“**Assignor**”), has (a) acquired the entire right, title and interest, for the United States and elsewhere throughout the world, in and to said the patents and applications, and inventions disclosed therein, identified in Schedule A-1, attached hereto and incorporated by this reference herein including any and all divisions, continuations, continuations-in-part thereof, and any and all Letters Patent which may be granted thereon, including any and all renewals, reissues, reexaminations, extensions, adjustments and prolongations thereof, (b) provided Know-How as defined below and in that certain License Agreement between Assignor and Organon International GmbH (“**Organon**”) dated July 26, 2021 (the “**Organon License**”) to Organon and provided Licensee Know-How as defined in that certain License Agreement by and between Assignor and Ares Trading SA (“**Merck Serono**”) dated June 10, 2015 (the “**Merck Serono License**”) and (c) entered into the Organon License as licensor and the Merck Serono License as Licensee (collectively, the Organon License and the Merck-Serono License are hereinafter referred to as the “**Licenses**”);

AND WHEREAS, **XOMA (US) LLC**, a Delaware limited liability company having its principal place of business at 2200 Powell Street, Suite 310, Emeryville, CA 94608 (“**Assignee**”) is desirous of acquiring the entire right, title and interest, for the United States and elsewhere throughout the world, in and to said Patent Rights, Know-How and Licenses;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby sells, assigns, transfers, and conveys to Assignee pursuant to that certain IP Acquisition Agreement dated as of November 21, 2022, by and between Assignor and Assignee, all of Assignor's right, title, and interest, for the United States and elsewhere throughout the world in and to:

- a) the patents and patent applications set forth on Schedule A-1, attached hereto and incorporated by this reference herein, and all patents that issue from such patent applications, and all continuations, and continuations-in-part, and divisionals, and extensions, adjustments, prolongations and substitutions, and reissues, and re-examinations, and renewals, of any of the foregoing and any and all Letters Patent which may be granted thereon (“**Patents**”), and any other patents or patent applications that claim a benefit or priority from any Patents, and inventions disclosed and claimed in any of the foregoing, and rights to apply for new patents with respect to any of the foregoing (collectively “**Acquired Patents**” and such assignment, the “**Assignment of Patents**”);
- b) all present and future scientific, technical, or commercial information, results and data of any type whatsoever that is not in the public domain or otherwise publicly known, including databases, inventions, improvements, practices, research, methods, discoveries, developments, technology, protocols, specifications, formulae, software, algorithms, knowledge, know-how, trade secrets, processes, assays, skills, experience, chemical or biological materials, reagents, formulations, expertise, techniques, results of experimentation and testing, data (including pharmacological, biological, chemical, biochemical, toxicological, pre-

clinical and clinical data and analytical and quality control data, stability data and other study data), CMC information, manufacturing process and development, and results in all cases, whether or not patentable, in written, electronic, tangible, intangible or any other form now known or hereafter developed, but excluding any patent rights and trademark rights, supplied or licensed by Seller pursuant to either of the Licenses (collectively, "Know-How"); and

- c) all licenses and similar contractual rights or permissions, whether exclusive or nonexclusive, related to any of the Acquired Patents or Merck Serono Patents, including those licenses set forth on Schedule A-2, attached hereto and incorporated by this reference herein,

in each case, together with all rights to income, royalties, and license fees deriving from the foregoing and claims and causes of action with respect to any of the foregoing, including without limitation all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, misappropriation, violation, breach, or default, and all other rights, privileges, and protections of any kind whatsoever of Assignor accruing under any of the foregoing provided by any applicable law, treaty, or international convention, said Assignee and its assigns and legal representatives to have, hold, exercise and enjoy the same with all the rights, powers, privileges, and advantages in any ways arising from or pertaining thereto, for and during the term or terms of any and all such Letters Patent when granted, including any and all renewals, reissues, reexaminations, extensions, adjustments and prolongations thereof, for the use and benefit of said Assignee and its assigns and legal representatives in as ample and beneficial a manner to all intents and purposes as the said Assignor might or could have held and enjoyed the same, as if this assignment had not been made (collectively, "Acquired Rights").

AND said Assignor hereby agrees to execute, without charge to Assignee all papers necessary or useful to file applications and secure Letters Patents thereon in the United States and elsewhere throughout the world for all Acquired Rights and to perfect assignment of the same to said Assignee, or any assignee acquiring title to said Patents, and agrees to perform, without charge to Assignee (except as otherwise permitted herein), all acts deemed necessary or desirable by Assignee to permit and assist Assignee in perfecting and enforcing the full benefits, enjoyment, rights, title and interest throughout the world in all Acquired Rights. Such acts may include execution of documents, including any and all powers of attorney, applications, assignments, declarations, affidavits, and any other papers in connection therewith reasonably necessary to perfect such benefits, enjoyment, rights, title and interest in Assignee, assistance and cooperation in the registration and enforcement of applicable intellectual property rights or other legal proceedings, including providing documents and materials in the possession or control of, Assignor testifying in any legal proceedings, signing lawful papers and making all lawful oaths, and generally doing everything that is reasonably necessary to aid Assignee in obtaining and enforcing proper protection for applicable intellectual property rights. If Assignee is unable for any reason, after reasonable effort, to secure Assignor's signature on any document needed in connection with the actions specified herein Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as Assignor's agent and attorney-in-fact, which appointment is coupled with an interest, to act for and on Assignor's behalf to execute, verify and file any such documents and to do all other lawfully permitted acts

to further the purposes of this Assignment with the same legal force and effect as if executed by Assignor.

AND said Assignor hereby authorizes and requests the Commissioner for Patents in the United States Patent and Trademark Office and the officials of corresponding entities or agencies elsewhere throughout the world to record and register this Assignment of Patents upon request by Assignee, and to issue Letters Patent on all Patent Rights to said Assignee, its assigns and legal representatives, in accordance herewith.

IN WITNESS WHEREOF, the undersigned has caused this Assignment of Patents, Know-How, and Licenses to be executed on this 21st day of November, 2022, by its duly authorized officer.

**SCHEDULE A-1**  
**Acquired Patents**

**Patents**

<b>Title</b>	<b>Jurisdiction</b>	<b>Patent Number</b>	<b>Issue Date</b>	<b>Record Owner</b>
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Albania	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Austria	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Australia	2017205254	02-Sep-2021	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Belgium	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Bulgaria	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Switzerland	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE	Cyprus, Republic of	3397622	09-Mar-2022	ObsEva S.A

AND SALT FORM, CRYSTAL POLYMORPH THEREOF				
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Czech Republic	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Germany	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Denmark	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Eurasian Patent Organization	039545	09-Feb-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Estonia	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	European Patent Convention	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Spain	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Finland	3397622	09-Mar-2022	ObsEva S.A

ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	France	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	United Kingdom	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Greece	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Croatia	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Hungary	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Ireland	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Israel	260286	02-May-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	India	381470	09-Nov-2021	ObsEva S.A



ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Iceland	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Italy	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Liechtenstein	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Lithuania	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Luxembourg	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Latvia	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Monaco	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	North Macedonia	3397622	09- Mar- 2022	ObsEva S.A

ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Malta	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Mexico	389261	10- Jan- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Netherlands	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Norway	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Poland	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Portugal	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Romania	3397622	09- Mar- 2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Serbia	3397622	09- Mar- 2022	ObsEva S.A

ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Sweden	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Singapore	11201804789Q	07-Oct-2020	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Slovenia	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Slovakia	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	San Marino	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Turkey	3397622	09-Mar-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Ukraine	125118	12-Jan-2022	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	United States of America	10,555,934	11-Feb-2020	ObsEva S.A

## Patent Applications

Title	Jurisdiction	Application/ Publication Number	Filing Date	Record Owner
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Australia	2021218003	04-Jan-2017	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Brazil	BR112018013597-6/BR112018013597-6 A2	04-Jan-2017	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Canada	3,009,573/3009573	04-Jan-2017	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	China (People's Republic)	201780012804.5/CN109790133A	04-Jan-2017	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Eurasian Patent Organization	202192959	04-Jan-2017	ObsEva S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	European Patent Convention	22153566.9	04-Jan-2017	ObsEva S.A

ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Hong Kong	19123217.2	04-Jan-2017	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Indonesia	P-00201804811	04-Jan-2017	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Israel	289256	04-Jan-2017	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Japan	2018-529284/2019-500351	04-Jan-2017	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Japan	2022-166814	04-Jan-2017	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Korea, Republic of	10-2018-7018312/10-2018-0100120	04-Jan-2017	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Mexico	MX/a/2022/000154	04-Jan-2017	ObsE va S.A

ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Singapore	10202009723P	30-Sep-2020	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	United States of America	62/274,674	04-Jan-2016	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	United States of America	62/395,664	16-Sep-2016	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	United States of America	62/407,918	13-Oct-2016	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	United States of America	16/752,961/US 2020-0155515 A1	27-Jan-2020	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	United States of America	17/984,833	10-Nov-2022	ObsE va S.A
ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	Patent Cooperation Treaty	PCT/EP2017/050099/2017/18639	04-Jan-2017	ObsE va S.A

ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF	South Africa	2018/03785	04-Jan-2017	ObsE va S.A
COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR	United States of America	62/672,278	16-May - 2018	ObsE va S.A
COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR	United States of America	16/411,974	14-May - 2019	ObsE va S.A
COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR	United States of America	62/815,077	07-Mar-2019	ObsE va S.A
COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR	United States of America	63/114,233	16-Nov-2020	ObsE va S.A
COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR	Patent Cooperation Treaty	PCT/EP2021/081794/WO 2022/101495	16-Nov-2021	ObsE va S.A

OBSEVA SA

By: Will Brown

Name: Will Brown

Title: Chief Financial Officer

**ACKNOWLEDGMENT**

STATE OF COLORADO )

) ss.

COUNTY OF DOUGLAS )


On the 21st day of November, 2022, before me personally appeared Will Brown, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the foregoing instrument, who, being duly sworn, did depose and say that he executed the same in his authorized capacity as the Chief Financial Officer of OBSEVA SA, the Swiss Corporation described, and acknowledged the instrument to be his free act and deed/ the free act and deed of OBSEVA SA for the uses and purposes mentioned in the instrument.

Delores M. Stump

Notary Public

Printed Name: Delores M. Stump

My Commission Expires: 9 July 2026





AGREED TO AND ACCEPTED:

XOMA (US) LLC

By: 

Name: Jim Neal

Title: Chief Executive Officer

**ACKNOWLEDGMENT**

STATE OF CALIFORNIA

)

) ss.

COUNTY OF \_\_\_\_\_

)

On the \_\_\_\_ day of November, 2022, before me personally appeared, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the foregoing instrument, who, being duly sworn, did depose and say that he executed the same in his authorized capacity as the Chief Executive Officer of Xoma (US) LLC, the Delaware limited liability corporation described, and acknowledged the instrument to be his free act and deed/the free act and deed of Assignee for the uses and purposes mentioned in the instrument.

\_\_\_\_\_  
Notary Public

Printed Name:

My Commission Expires: \_\_\_\_\_

SEE ATTACHED NOTARY

*[Signature Page to the Assignment Agreement]*

**CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT**

**CIVIL CODE § 1189**

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California )

County of Contra Costa )


On November 19, 2022 before me, J. C Buntin, Notary Public

Personally appeared James Neal

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.



Signature [Signature]  
Signature of Notary Public

*Place Notary Seal Above*

**OPTIONAL**

*Though this section is optional, completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.*

**Description of Attached Document**

Title or Type of Document: \_\_\_\_\_ Document Date: \_\_\_\_\_

Number of Pages: \_\_\_\_\_ Signer(s) Other Than Named Above: \_\_\_\_\_

**Capacity(ies) Claimed by Signer(s)**

Signer's Name: \_\_\_\_\_

☐ Corporate Officer — Title(s): \_\_\_\_\_

☐ Partner — ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: \_\_\_\_\_

Signer Is Representing: \_\_\_\_\_

Signer's Name: \_\_\_\_\_

☐ Corporate Officer — Title(s): \_\_\_\_\_

☐ Partner — ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: \_\_\_\_\_

Signer Is Representing: \_\_\_\_\_